Pre-order Enquiry
Download Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
In situ hybridization (ISH) is a type of hybridization that uses a labeled complementary DNA, RNA or modified nucleic acids strand to localize a specific DNA or RNA sequence in a portion or section of tissue (in situ), or, if the tissue is small enough, in the entire tissue, in cells, and in circulating tumor cells (CTCs). This is distinct from immunohistochemistry, which usually localizes proteins in tissue sections.
researcher's newest research report, the “In Situ Hybridization Industry Forecast” looks at past sales and reviews total world In Situ Hybridization sales in 2022, providing a comprehensive analysis by region and market sector of projected In Situ Hybridization sales for 2023 through 2029. With In Situ Hybridization sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world In Situ Hybridization industry.
This Insight Report provides a comprehensive analysis of the global In Situ Hybridization landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on In Situ Hybridization portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global In Situ Hybridization market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for In Situ Hybridization and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global In Situ Hybridization.
The global In Situ Hybridization market size is projected to grow from US$ 533.4 million in 2022 to US$ 675.1 million in 2029; it is expected to grow at a CAGR of 3.4% from 2023 to 2029.
North America is expected to account for the largest share of the market in 2018. This can be attributed to growing clinical and research in cancer by biotechnology and pharmaceutical companies, government initiatives, increasing prevalence and diagnosis of cancer in the U.S. and Canada, and increasing adoption of companion diagnostics. Increased adoption of companion diagnostics is attributed to the development and launch of newer therapeutic agents. However, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period. This can be attributed to the growing presence of international players in China and India, increasing cancer prevalence and diagnosis, and increased healthcare expenditure across the Asia-Pacific region are drivers for the in situ hybridization market in this region.
This report presents a comprehensive overview, market shares, and growth opportunities of In Situ Hybridization market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Fluorescence In Situ Hybridization (FISH)
Chromogenic In Situ Hybridization
Segmentation by application
Cancer Diagnosis
Immunology
Neuroscience
Cytology
Infectious Diseases
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott Laboratories
Roche
Thermo Fisher Scientific
Merck
Agilent Technologies
Perkin Elmer
Danaher
Exiqon
Biogenex Laboratories
Advanced Cell Diagnostics
Bio Sb
researcher's newest research report, the “In Situ Hybridization Industry Forecast” looks at past sales and reviews total world In Situ Hybridization sales in 2022, providing a comprehensive analysis by region and market sector of projected In Situ Hybridization sales for 2023 through 2029. With In Situ Hybridization sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world In Situ Hybridization industry.
This Insight Report provides a comprehensive analysis of the global In Situ Hybridization landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on In Situ Hybridization portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global In Situ Hybridization market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for In Situ Hybridization and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global In Situ Hybridization.
The global In Situ Hybridization market size is projected to grow from US$ 533.4 million in 2022 to US$ 675.1 million in 2029; it is expected to grow at a CAGR of 3.4% from 2023 to 2029.
North America is expected to account for the largest share of the market in 2018. This can be attributed to growing clinical and research in cancer by biotechnology and pharmaceutical companies, government initiatives, increasing prevalence and diagnosis of cancer in the U.S. and Canada, and increasing adoption of companion diagnostics. Increased adoption of companion diagnostics is attributed to the development and launch of newer therapeutic agents. However, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period. This can be attributed to the growing presence of international players in China and India, increasing cancer prevalence and diagnosis, and increased healthcare expenditure across the Asia-Pacific region are drivers for the in situ hybridization market in this region.
This report presents a comprehensive overview, market shares, and growth opportunities of In Situ Hybridization market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Fluorescence In Situ Hybridization (FISH)
Chromogenic In Situ Hybridization
Segmentation by application
Cancer Diagnosis
Immunology
Neuroscience
Cytology
Infectious Diseases
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott Laboratories
Roche
Thermo Fisher Scientific
Merck
Agilent Technologies
Perkin Elmer
Danaher
Exiqon
Biogenex Laboratories
Advanced Cell Diagnostics
Bio Sb
Frequently Asked Questions
This market study covers the global and regional market with an
in-depth analysis of the
overall growth prospects...
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by
highlighting information on
different aspects including drivers, restraints...
